UK Regulator Tests Using Consultancy Firms To Monitor GMP, GDP Compliance
Novel Approach Aims To Do Away With Frequent On-Site MHRA Inspections
Executive Summary
The MHRA is testing the feasibility of appointing eligible external consultants to be its eyes and ears when it comes to checking up on drug companies that have failed to meet good manufacturing and distribution practice requirements.
You may also be interested in...
UK MHRA Specifies Eligibility For Consultancy Firms To Monitor GMP, GDP Compliance
Consultancy firms must have at least five years of experience in carrying out independent GMP or GDP audits if they want to apply to become a “compliance monitor” under a new MHRA scheme to keep track of drug companies that fail to comply with GMP/GDP requirements.
UK MHRA Considers Additional Inspection Fees For Non-Compliance
The UK medicines regulator is planning to levy additional fees to recover the costs associated with the extra time spent by inspectors in following up or reviewing non-compliance cases referred for further action.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.